Royalty Pharma enters $350M synthetic royalty funding agreement with Syndax
PremiumThe FlyRoyalty Pharma enters $350M synthetic royalty funding agreement with Syndax
5d ago
Syndax, Royalty Pharma enter $350M royalty funding agreement for Niktimvo
Premium
The Fly
Syndax, Royalty Pharma enter $350M royalty funding agreement for Niktimvo
5d ago
SNDX Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
SNDX Upcoming Earnings Report: What to Expect?
7d ago
Syndax and Incyte announce publication of positive Niktimvo results in GVHD
PremiumThe FlySyndax and Incyte announce publication of positive Niktimvo results in GVHD
2M ago
Syndax price target raised to $34 from $30 at Citi
Premium
The Fly
Syndax price target raised to $34 from $30 at Citi
3M ago
Syndax price target raised to $45 from $41 at H.C. Wainwright
Premium
The Fly
Syndax price target raised to $45 from $41 at H.C. Wainwright
3M ago
Syndax reports data from Phase 2 portion of AUGMENT-101 trial of revumenib
PremiumThe FlySyndax reports data from Phase 2 portion of AUGMENT-101 trial of revumenib
3M ago
Syndax reports Q2 EPS (80c), consensus (91c)
Premium
The Fly
Syndax reports Q2 EPS (80c), consensus (91c)
3M ago
Syndax treatment of acute leukemias of ambiguous lineage granted orphan status
Premium
The Fly
Syndax treatment of acute leukemias of ambiguous lineage granted orphan status
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100